drugset / Trial / NCT04510636
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.
Timeline
- Start
- 2021-12-20
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |